Urgent Recall: Blood Pressure Medication Tainted with Cancer-Causing Chemical

Teva Pharmaceuticals USA has initiated a significant nationwide recall of over half a million bottles of Prazosin Hydrochloride capsules, a medication commonly prescribed for high blood pressure and sometimes used to treat PTSD-related nightmares. The recall stems from the discovery of elevated levels of a potentially cancer-causing chemical, N-nitroso Prazosin impurity C, exceeding acceptable safety limits set by the U.S. Food and Drug Administration (FDA).

What is Prazosin Hydrochloride?

Prazosin Hydrochloride is an alpha-blocker medication primarily used to treat hypertension, or high blood pressure, by relaxing blood vessels and improving blood flow. Beyond its primary use, it is also frequently prescribed off-label to manage symptoms of post-traumatic stress disorder (PTSD), particularly to alleviate severe nightmares and other sleep disturbances associated with the condition.

The Cause for Concern: Nitrosamine Impurities

The core issue leading to this recall is the presence of N-nitroso Prazosin impurity C, a type of nitrosamine. Nitrosamines are a class of chemical compounds that can form naturally in the environment and are found in small, safe amounts in various foods and drinking water. However, during the manufacturing or storage processes of certain medications, these impurities can form in quantities that are considered potentially carcinogenic.

According to the FDA, tests conducted on the affected lots of Prazosin Hydrochloride indicated levels of this specific nitrosamine impurity that were above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit. This finding prompted Teva Pharmaceuticals to issue a voluntary recall, which the FDA subsequently classified as a Class II risk.

Understanding the Class II Recall

A Class II recall, as defined by the FDA, signifies a situation where "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." While the immediate risk of severe harm is considered low, the long-term implications of exposure to elevated carcinogen levels necessitate this precautionary measure.

Affected Products and How to Check

The recall, initially launched on October 7, 2025, and classified by the FDA on October 24, 2025, encompasses more than 580,000 bottles of Prazosin Hydrochloride capsules distributed across the country. The affected dosages and approximate bottle counts are:

• 1 mg capsules: 181,659 bottles
• 2 mg capsules: 291,512 bottles
• 5 mg capsules: 107,673 bottles

These capsules were sold in various bottle sizes, including 100-count, 250-count, 500-count, and 1,000-count, with expiration dates ranging from October 2025 through February 2027. Patients currently taking Prazosin Hydrochloride are strongly advised to check the lot number and expiration date on their medication bottles. A comprehensive list of specific lot codes and expiration dates can be found through official FDA enforcement reports, which can be accessed via reliable health news sources like digitaltrendstoday.com.

Guidance for Patients

It is crucial for patients not to discontinue their medication abruptly without consulting a healthcare professional. Stopping Prazosin Hydrochloride suddenly can lead to dangerous health consequences, especially for individuals managing high blood pressure or severe PTSD symptoms. If your medication is part of the recalled lots, contact your doctor or pharmacist immediately for guidance on how to proceed. They can provide instructions on safely returning the affected medication and arranging for a safe replacement.

Broader Context of Nitrosamine Contamination

This is not an isolated incident. Nitrosamine impurities have been a recurring concern in the pharmaceutical industry, leading to recalls of other widely used medications from various manufacturers, including statins for cholesterol management. This ongoing issue underscores the rigorous vigilance required in drug manufacturing and the importance of continuous testing and regulatory oversight to ensure patient safety.

Patients are encouraged to stay informed about medication recalls and to always consult their healthcare providers with any concerns regarding their prescriptions.